These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 28025025)

  • 1. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
    Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
    J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
    Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
    Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
    N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
    Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
    Snelder N; Heinig R; Drenth HJ; Joseph A; Kolkhof P; Lippert J; Garmann D; Ploeger B; Eissing T
    Clin Pharmacokinet; 2020 Mar; 59(3):359-370. PubMed ID: 31583611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China.
    Zhou J; Kang L; Gu C; Li X; Guo X; Fang M
    Ren Fail; 2024 Dec; 46(2):2400541. PubMed ID: 39248389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
    Sarafidis P; Agarwal R; Pitt B; Wanner C; Filippatos G; Boletis J; Tuttle KR; Ruilope LM; Rossing P; Toto R; Anker SD; Liu ZH; Joseph A; Ahlers C; Brinker M; Lawatscheck R; Bakris G;
    Clin J Am Soc Nephrol; 2023 May; 18(5):602-612. PubMed ID: 36927680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
    N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
    J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.
    Wada T; Inagaki M; Yoshinari T; Terata R; Totsuka N; Gotou M; Hashimoto G
    Clin Exp Nephrol; 2021 Feb; 25(2):120-130. PubMed ID: 32974732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.
    Koomen JV; Stevens J; Mostafa NM; Parving HH; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Aug; 20(8):2019-2022. PubMed ID: 29603851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
    Pena MJ; de Zeeuw D; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Kohan DE; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; Sharma S; Corringham T; Sharma K; Heerspink HJL
    Diabetes Obes Metab; 2017 May; 19(5):749-753. PubMed ID: 28019071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease.
    Zheng Y; Ma S; Huang Q; Fang Y; Tan H; Chen Y; Li C
    Kidney Blood Press Res; 2022; 47(4):219-228. PubMed ID: 35034019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS;
    JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.